TIDMPYC

RNS Number : 0202H

Physiomics PLC

25 July 2023

25 July 2023

Physiomics plc

("PYC" or the "Company")

Director Dealing

The Company announces that Dr Jim Millen, Chief Executive Officer of Physiomics, has transferred, for no consideration, 500,000 ordinary shares of 0.4p each in the Company held in certificated form ("Ordinary Shares") to his nominee account with Interactive Investor Services Limited. The Ordinary Shares remain beneficially owned by Dr Millen.

Accordingly, Dr Millen's total holding in the Company will remain unchanged at 1,884,393 Ordinary Shares, representing approximately 1.39 per cent. of the Company's issued share capital.

Enquiries:

Physiomics plc

Dr Jim Millen, CEO +44 (0)1865 784 980

Hybridan LLP (Broker) +44 (0) 203 764 2341

Claire Louise Noyce

Strand Hanson Ltd (NOMAD) +44 (0)20 7409 3494

James Dance

James Bellman

The Company's LEI is 213800A71DSZ6ABMTQ91

PDMR Notification Forms

 
 1.   Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                              James Millen 
     --------------------------------  ---------------------------------------- 
 2.   Reason for the Notification 
     -------------------------------------------------------------------------- 
 a)   Position/status                   Executive Chairman and CEO 
     --------------------------------  ---------------------------------------- 
 b)   Initial notification/amendment    Initial notification 
     --------------------------------  ---------------------------------------- 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     -------------------------------------------------------------------------- 
 a)   Name                              Physiomics plc 
     --------------------------------  ---------------------------------------- 
 b)   LEI                               213800A71DSZ6ABMTQ91 
     --------------------------------  ---------------------------------------- 
 4.   Details of the transaction(s):section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv)each place where transactions have 
       been conducted 
     -------------------------------------------------------------------------- 
 a)   Description of the Financial      Physiomics plc Ordinary Shares 
       instrument, type of instrument 
     --------------------------------  ---------------------------------------- 
      Identification code               ISIN: GB00BDR6W943 
     --------------------------------  ---------------------------------------- 
 b)   Nature of the Transaction         Transfer of securities held in paper 
                                         share certificates to nominee account 
                                         Interactive Investor Services Nominees 
                                         Limited. 
     --------------------------------  ---------------------------------------- 
 c)   Price(s) and volume(s)            Dr Jim Millen Price(s)    Volume(s) 
                                          N/A         500,000 
                                                     ---------- 
     --------------------------------  ---------------------------------------- 
 d)        Aggregated information 
             *    Aggregated volume       500,000 
                                          N/A 
 
 
             *    Price 
     --------------------------------  ---------------------------------------- 
 e)   Date of the transaction           22 July 2023 
     --------------------------------  ---------------------------------------- 
 f)   Place of the transaction          Off market transaction 
     --------------------------------  ----------------------------------------

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour(TM) technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 100 projects, involving over 50 targets and 75 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHRIMRTMTMTBIJ

(END) Dow Jones Newswires

July 25, 2023 02:00 ET (06:00 GMT)

Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Physiomics.
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Physiomics.